Author

Lauren Crow

Institution: Johnson & Johnson (United States)

Observed institution: Johnson & Johnson (United States)

OpenAlex ID: A5134701870

Erdafitinib in Patients With Advanced Solid Tumors With FGFR Alterations (RAGNAR): Results of Tumor-Specific Analyses and Secondary Cohorts

2026 · Omar Carranza, Shubham Pant, et al. · JCO Precision Oncology · 1

Incidence and outcomes of FGFR inhibitor-associated retinopathy of patients treated with oral erdafitinib across the clinical trial program

2026 · Anne O’Hagan, Arlene Siefker-Radtke, et al. · The Oncologist

Implementation of a Systematic Patient Mobility Program Across 5 Hospitals

2026 · Daniel L. Young, Kevin McLaughlin, et al. · Journal of the American Medical Directors Association

Works count: 3

Citation count: 1

H-index: 1

I10-index: